Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 703

Sort by

Sort Order Select

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Sirpαfc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

Oleksandr Galkin, PhD, Jessica McLeod, BSc, James A Kennedy, MD PhD, Liqing Jin, MD, Nathan Mbong, Mark Wong, PhD, Bob Uger, PhD, Mark D. Minden, MD PhD, Jayne S Danska, PhD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 3906.

https://doi.org/10.1182/blood-2019-131018

Published: 2019

Journal Articles

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Guru Murthy, MBBS, Scott H. Kaufmann, MD PhD, Aniko Szabo, PhD, Arielle Baim, Ashish Anshu, Alexander Hinman, Laura C. Michaelis, MD, Sameem Abedin, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 3837.

https://doi.org/10.1182/blood-2019-131728

Published: 2019

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Xiaohong Liu, Wenbing Duan, Jing Wang, MD, Jinsong Jia, Lizhong Gong, Shen-ye Lu, MD, Xiaosu Zhao, PhD, Ying-Jun Chang, Yue-Yun Lai, Hongxia Shi, Yu Wang, Chenhua Yan, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 3823.

https://doi.org/10.1182/blood-2019-128505

Published: 2019

Journal Articles

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Daisuke Kaji, MD, Manabu Kusakabe, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Yasuhito Suehara, MD, Keiichiro Hattori, MD PhD, Yasunori Ota, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 4128.

https://doi.org/10.1182/blood-2019-127521

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Clostridium Difficile Infection Among Hematopoietic Stem Cell Transplant Recipients and Subsequent Development of Graft-Versus-Host Disease

Shanee Chung, MD, Yasser Abou Mourad, MD

Blood (2019) 134 (Supplement_1): 4494.

https://doi.org/10.1182/blood-2019-129663

Published: 2019

Journal Articles

EHMT2 Inhibitor BIX-01294 Induces Endoplasmic Reticulum Stress Mediated Apoptosis and Autophagy in Diffuse Large B Cell Lymphoma Cells

Linyan Xu, PhD, Xiang Gao, Wei Sang, MD, Dongmei Yan, Xuguang Song, Feng Zhu, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 2787.

https://doi.org/10.1182/blood-2019-127653

Published: 2019

Journal Articles

Title: SNP Microarray Reveals Predicted Outcomes of a Novel High Risk AML Subgroup with ERG Amplification

Sandra Mazzoni, BS,DO,MT(ASCP), Brian T. Hess, MD, Cynthia Schandl, MD PhD, Iya Znoyko, PhD, Georges Nahhas, Dongjun Chung, Assistant Professor, PhD, Yanna Ding, MD PhD, Daynna Wolff, PhD FACMG

Blood (2019) 134 (Supplement_1): 2737.

https://doi.org/10.1182/blood-2019-121408

Published: 2019

Journal Articles

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Ann Dahlberg, MD, Muna Qayed, MDMSc, Katherine Tarlock, MD, Jessica A. Pollard, MD, Filippo Milano, MD PhD, Soheil Meshinchi, MD PhD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 2614.

https://doi.org/10.1182/blood-2019-130979

Published: 2019

Journal Articles

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Erin Lynn Crowgey, PhD, Todd E Druley, MD PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2683.

https://doi.org/10.1182/blood-2019-131050

Published: 2019

Journal Articles

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Zachary D. Epstein-Peterson, MD, Barbara Spitzer, MD, Joseph McCarter, PhD, Erin McGovern, BA, Ross L. Levine, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 2708.

https://doi.org/10.1182/blood-2019-123400

Published: 2019

Journal Articles

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

Amy N Sexauer, MD PhD, Brian Do, David B Sykes, MD PhD

Blood (2019) 134 (Supplement_1): 2712.

https://doi.org/10.1182/blood-2019-128910

Published: 2019

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3081.

https://doi.org/10.1182/blood-2019-131914

Published: 2019

Journal Articles

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Diego Villa, MD MPH, Laurie H Sehn, MD, Kerry J Savage, BSc, MD MSc, Cynthia L Toze, MD FRCPC, Kevin Song, MD, Wendie L den Brok, Ciara L Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 2814.

https://doi.org/10.1182/blood-2019-124217

Published: 2019

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Guido Gini, MD, Monica Tani, Alessandra Tucci, MD, Renato Bassan, MD, Filippo Ballerini, MD, Michela Sampaolo, Francesco Merli, MD, Francesca Re, Attilio Olivieri, Ombretta Annibali, Anna Marina Liberati, Carlo Visco, Annalisa Arcari, MD, Sergio Storti, MD, Alberto Fabbri, MD, Gerardo Musuraca, MD, Vittorio Ruggero Zilioli, MD, M. Christina Cox, MD PhD, Stefano Luminari, MD

Blood (2019) 134 (Supplement_1): 2880.

https://doi.org/10.1182/blood-2019-126568

Published: 2019

Journal Articles

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Fahrettin Covut, MD, Gayathri Ravi, MD, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 3174.

https://doi.org/10.1182/blood-2019-126059

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sirpαfc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Clostridium Difficile Infection Among Hematopoietic Stem Cell Transplant Recipients and Subsequent Development of Graft-Versus-Host Disease

EHMT2 Inhibitor BIX-01294 Induces Endoplasmic Reticulum Stress Mediated Apoptosis and Autophagy in Diffuse Large B Cell Lymphoma Cells

Title: SNP Microarray Reveals Predicted Outcomes of a Novel High Risk AML Subgroup with ERG Amplification

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only